205:, at the Human Genome Organization Workshop on DNA arrays, Tartu, Estonia, May 23-26th, 1999, invited presentation, and at the GBM99 fall meeting of the German Society for Biochemistry and Molecular Biology, Hamburg, Germany, September 6-8th, 1999, invited presentation
23:, a Swiss-based biotechnology company, now part of Merck-Serono, by private founders. Its aim was to provide preventive and curative treatment guidelines for common and complex diseases. These guidelines were envisaged as composed of two parts:
189:, L. Farinelli, G. Matton, C. Adessi, G. Turcatti, J.J. Mermod, E. Kawashima, presented at the Fifth International Automation in Mapping and DNA Sequencing Conference, St. Louis (MO, USA), October 7–10, 1998, invited presentation.
50:
and
Laurent Farinelli. This work has been protected by several patents and patents applications, publications and was discussed in presentations at international conferences from 1998 to 2001.
289:
294:
299:
151:"Solid phase DNA amplification: characterisation of primer attachment and amplification mechanisms." C. Adessi, G. Matton, G. Ayala, G. Turcatti,
190:
120:
185:"A very large scale, high throughput and low cost DNA sequencing method based on a new 2-dimensional DNA auto-patterning process",
46:
technology whose development had been initiated in late 1996 at Glaxo-Welcome's Geneva
Biomedical Research Institute (GBRI), by
38:
The company was basing its strategy on the development of so-called "DNA colony sequencing" technology (now commercialized by
19:
S.A. (initially incorporated under the name "GenInEx S.A.") was a start-up company created in
November 2000 as a spin-off of
53:
By the end of 2003, while the company was progressing along its plans towards realizing an industrial instrument capable of
43:
109:
214:"Genomic information extraction using massively parallel sequencing approaches on self-forming DNA microchips",
168:"Solid Phase DNA Amplification: A Simple Monte Carlo Lattice Model", Jean-Francois Mercier, Gary W. Slater, and
284:
74:
57:
a complete human genome in approximately 24 hours, strategic considerations led the main shareholder (
244:, invited presentation at the Nanotech2001 conference, Montreux, Switzerland, November 27-29th, 2001
100:, see Numéro d'enregistrement:CH-550.1.020.166-8 Registre du commerce du Canton de Vaud, Switzerland
218:, at the Eurobiochips 2000 IBC conference, Hamburg, Germany June 5–7th, 2000. Invited presentation
191:
http://www.slideshare.net/pascalmayer/dna-colony-massively-parrallel-sequencing-ams98-presentation
231:, invited presentation at Nanotech 2000 conference, Montreux, Switzerland, November 26-30th, 2000
62:
39:
253:
97:
61:) to sell Manteia's colony DNA sequencing technology to UK based Solexa Ltd, now part of
131:
93:
278:
240:"NA sequencing on self-forming micro-arrays: towards 1 million bases/second/setup",
241:
228:
215:
202:
186:
169:
152:
47:
54:
96:, Francisco Rubio-Sandi, Daniel Valtueña-Maistre, Laurent Farinelli,
58:
28:
20:
227:"Self-forming DNA micro-arrays and their applications to genomics",
201:"High density DNA arrays obtained by a new autopatterning process",
34:
an
Internet link to a treatment database to be referenced by doctors
142:
patents WO 9844151, WO 9844152, WO 0018957, WO 0246456, WO 03074734
121:
DNA colony massively parallel sequencing ams98 presentation
110:
Manteia non-confidential 09-2003 corporate presentation
268:vol. 26, pp. 1135–1145, "Illumina Genome Analyzer"
27:a "personal genome card" containing the entire
8:
290:Biotechnology companies established in 2000
86:
31:sequence of the person holding the card
295:Biotechnology companies of Switzerland
7:
264:Shendure J. & Hanlee J. (2008)
300:2000 establishments in Switzerland
14:
155:, J.J. Mermod and E. Kawashima.
176:2003 October; 85(4): 2075–2086.
1:
254:Illumina – Solexa Technology
44:massive parallel sequencing
17:Manteia Predictive Medicine
316:
75:Illumina dye sequencing
157:Nucleic Acids Research
266:Nature Biotechnology
174:Biophysical Journal
42:), its proprietary
63:Illumina (company)
307:
269:
262:
256:
251:
245:
238:
232:
225:
219:
212:
206:
199:
193:
183:
177:
166:
160:
149:
143:
140:
134:
129:
123:
118:
112:
107:
101:
98:Gerardo Turcatti
91:
315:
314:
310:
309:
308:
306:
305:
304:
275:
274:
273:
272:
263:
259:
252:
248:
239:
235:
226:
222:
213:
209:
200:
196:
184:
180:
167:
163:
159:(2000), 28, e87
150:
146:
141:
137:
130:
126:
119:
115:
108:
104:
92:
88:
83:
71:
12:
11:
5:
313:
311:
303:
302:
297:
292:
287:
285:DNA sequencing
277:
276:
271:
270:
257:
246:
233:
220:
207:
194:
178:
161:
144:
135:
124:
113:
102:
85:
84:
82:
79:
78:
77:
70:
67:
36:
35:
32:
13:
10:
9:
6:
4:
3:
2:
312:
301:
298:
296:
293:
291:
288:
286:
283:
282:
280:
267:
261:
258:
255:
250:
247:
243:
237:
234:
230:
224:
221:
217:
211:
208:
204:
198:
195:
192:
188:
182:
179:
175:
171:
165:
162:
158:
154:
148:
145:
139:
136:
133:
128:
125:
122:
117:
114:
111:
106:
103:
99:
95:
90:
87:
80:
76:
73:
72:
68:
66:
64:
60:
56:
51:
49:
45:
41:
33:
30:
26:
25:
24:
22:
18:
265:
260:
249:
236:
223:
210:
197:
181:
173:
170:Pascal Mayer
164:
156:
147:
138:
132:Pascal Mayer
127:
116:
105:
94:Pascal Mayer
89:
52:
48:Pascal Mayer
37:
16:
15:
279:Categories
81:References
55:sequencing
242:P. Mayer
229:P. Mayer
216:P. Mayer
203:P. Mayer
187:P. Mayer
153:P. Mayer
69:See also
40:Illumina
59:Serono
29:genome
21:Serono
281::
172:,
65:.
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.